<DOC>
	<DOCNO>NCT00058370</DOCNO>
	<brief_summary>RATIONALE : Radioimmunotherapy us radiolabeled monoclonal antibody locate tumor cell deliver radioactive tumor-killing substance without harm normal cell . Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining intrathecal radioimmunotherapy radiation therapy combination chemotherapy may kill tumor cell remain surgery . PURPOSE : Phase II trial study effectiveness combine intrathecal radioimmunotherapy radiation therapy combination chemotherapy treat patient undergone surgery medulloblastoma .</brief_summary>
	<brief_title>Intrathecal Radioimmunotherapy , Radiation Therapy , Chemotherapy After Surgery Treating Patients With Medulloblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility combine post-operative intrathecal radioimmunotherapy , craniospinal radiotherapy intensity-modulated radiotherapy boost , chemotherapy patient standard-risk medulloblastoma . - Determine whether regimen maintain exceed current progression-free survival rate decrease long-term serious morbidity patient . - Determine long-term morbidity , specifically neuropsychological , neuroendocrine , audiometric , growth outcome , patient treat regimen . OUTLINE : - Radioimmunotherapy : Patients receive intrathecal iodine I 131 monoclonal antibody 3F8 day 1 8 . - Radiotherapy : Beginning soon possible radioimmunotherapy , patient undergo external-beam intensity-modulated radiotherapy 5 day week 6 week . - Chemotherapy : Patients receive vincristine IV weekly 8 week concurrently radiotherapy . Beginning 6 week completion radiotherapy ( 4 week vincristine ) , patient receive cisplatin IV 6 hour oral lomustine day 0 vincristine IV day 0 , 7 , 14 . Treatment repeat every 6 week 8 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 6-20 patient accrue study within 3.2 year .</detailed_description>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients must histologic proof medulloblastoma review Department Pathology Memorial SloanKettering Cancer Center . Patients must begin study prescribe therapy within 42 day neurosurgical resection tumor Age ≥ 3yearsold . Postoperative head MRI must confirm ≤ 1.5 cm2 residual tumor present . Head spine MRI lumbar CSF cytology must show definitive evidence leptomeningeal dissemination ( Chang stage M0 ) . Examinations evaluate extraneural site mandate , perform clinical indication must free metastatic disease . No prior RT chemotherapy medulloblastoma permit Patients must adequate CSF flow ( defined lack compartmentalization ) 111Indium DTPA flow study . Patients must adequate organ function define : Hepatic : total bilirubin &lt; 2.0 mg/dl , AST &lt; 3 x upper limit normal . Renal : Calculated creatinine clearance nuclear GFR ≥ 70 ml/min/1.73 m^2 . The patient , minor , parent legal guardian , must give informed write consent indicate aware investigational nature study . EXCLUSION CRITERIA : Unable start study prescribe therapy within 42 day neurosurgical resection tumor Age le 3 year &gt; 1.5 cm2 residual tumor postoperative head MRI Evidence leptomeningeal dissemination head spine MRI CSF cytology positivity Evidence extraneural metastasis Prior radiation therapy chemotherapy medulloblastoma Inadequate CSF flow 111Indium DTPA flow study Patients sign symptom suggestive increase intracranial pressure ( headache , emesis , ocular paresis ) eligible clear neurology and/or neurosurgery . Pregnancy Total bilirubin ≥ 2.0 mg/dl AST ≥ 3 x upper limit normal Creatinine clearance GFR &lt; 70 ml/min/1.73 m^2</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>adult medulloblastoma</keyword>
	<keyword>untreated childhood medulloblastoma</keyword>
</DOC>